Neonates with congenital diaphragmatic hernia (CDH) suffer from a diaphragmatic defect, lung hypoplasia, and pulmonary hypertension, with poor lung function forming the major clinical challenge. Despite prenatal diagnosis and advanced postnatal treatment strategies, the mortality rate of CDH is still high. CDH has been subject of extensive research over the past decades, but its etiology remains unknown. A major problem with CDH is the failure to predict the individual response to treatment modalities like high-frequency ventilation, inhaled nitric oxide, and extracorporeal membrane oxygenation. In this study, we tested the possibility that CDH lungs are surfactant protein deficient, which could explain the respiratory failure and difficulties in treating CDH infants. We investigated this hypothesis in the nitrofeninduced CDH rat model and assessed the cellular concentrations of surfactant protein (SP)-A, -B, and -C mRNA with a quantitative radioactive in situ hybridization technique. No differences were observed between control and CDH lungs for SP mRNA expression patterns. The cellular concentration (mean OD) of SP-A and SP-B mRNA was similar at all stages whereas the mean OD of SP-C mRNA and the volume fraction of cells (% Area) expressing SP mRNA was higher in CDH lungs at term. Immunohistochemical analysis revealed no differences between control and CDH lungs for SP protein expression. No differences in the mean OD or % Area for the SP mRNAs were found between the ipsi-and contralateral side of CDH lungs. We conclude that there is no primary deficiency of surfactant proteins in the nitrofen-induced CDH rat model. CDH is an anomaly occurring 1 in 3000 live births (1). It is characterized by a diaphragmatic defect, severe lung hypoplasia, and pulmonary hypertension, and in 40% of the patients other severe birth defects such as cardiac abnormalities are present (2, 3). Despite years of extensive research, the etiology of CDH remains unknown (4). Clinically, pulmonary hypoplasia and pulmonary hypertension form the major problems in CDH (5).Many CDH studies have focused on treatment modalities such as conventional ventilation with gentle handling of the fragile lung, high-frequency ventilation, ECMO, in utero tracheal ligation with or without betamethasone injection, inhaled nitric oxide, and prenatal injections of betamethasone, TSHreleasing hormone, or a combination of both hormones. Although selected centers have reported improved survival (6, 7), the overall mortality rate, however, is still variably high, so that CDH continues to be a serious problem in the neonatal and pediatric surgical intensive care unit, with optimal treatment for CDH still the subject of ongoing debate (5, 8 -10